title: Are prophylactic antibiotics necessary during extracorporeal shockwave lithotripsy?
abstract: A randomised clinical study was carried out on patients admitted for ESWL treatment in order to establish the requirement for prophylactic treatment with antibiotics during this procedure. Patients with clinical signs of urinary tract infection, evidence of infectious stones or a positive urine culture were excluded. All other patients were consecutively randomised into 3 groups which were given either trimethoprim + sulphamethoxazole or mecillinam (Group A), methenamine hippurate (Group B), or no treatment at all (Group C). Evaluation with respect to clinical signs of infection was done immediately after the treatment and 4 weeks later. In addition, a urine culture was performed 2 weeks after ESWL, i.e. 1 week after completing treatment with antibiotics and methenamine hippurate. With respect to infectious complications there were no differences between Groups A and C, between Groups B and C or between Group A and B+C, whereas an unexplained slightly higher infectious rate was recorded for Group B compared with Group A. In all patients the occurrence of bacteriuria was low (6.7%) despite the fact that almost 30% of patients had a ureteric catheter during the ESWL procedure. Patients with ureteric catheters did not present with more infectious complications than those without. All patients had a bladder catheter during ESWL. It was concluded that prophylactic treatment with antibiotics during ESWL treatment is unnecessary in all situations where an infectious aetiology is unlikely.
authors.affiliation: Department of Urology, University Hospital, Linköping, Sweden.
authors.forename: B
authors.initials: B
authors.lastname: Pettersson
authors.forename: H G
authors.initials: HG
authors.lastname: Tiselius
mesh_terms: D000328:Adult; D000560:Amdinocillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000892:Anti-Infective Agents, Urinary / Q000627:therapeutic use; D001437:Bacteriuria / Q000517:prevention & control; D002986:Clinical Trials as Topic; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D006626:Hippurates / Q000627:therapeutic use; D006801:Humans; D008096:Lithotripsy; D008297:Male; D008709:Methenamine / Q000031:analogs & derivatives / Q000627:therapeutic use; D008875:Middle Aged; D011292:Premedication; D011897:Random Allocation; D013420:Sulfamethoxazole / Q000627:therapeutic use; D014295:Trimethoprim / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014545:Urinary Calculi / Q000382:microbiology / Q000628:therapy; D014546:Urinary Catheterization
chemical_list: D000900:Anti-Bacterial Agents; D000892:Anti-Infective Agents, Urinary; D004338:Drug Combinations; D006626:Hippurates; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D008709:Methenamine; D013420:Sulfamethoxazole; C011481:methenamine hippurate; D000560:Amdinocillin